

# Clinical trials of cholesterol lowering intervention for cardiovascular prevention in elderly

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 statins

Trial	Treatments	Patients	Trials design and methods
<b>fluvastatin vs placebo</b>			
<b>FLARE (elderly subgroup) , 1999</b> n=179/187 follow-up: 0.8y	-	CAD requiring PCI, subgroup of age 65-80 y	parallel groups double blind
<b>LIPS (elderly subgroup) , 2002</b> n=324/299 follow-up: 3.9y	-	CAD requiring PCI, subgroup of age 65-80 y	parallel groups double blind
<b>lovastatin vs placebo</b>			
<b>CRISP 20mg , 1994</b> [NCT00000477] n=NA follow-up: 1 years	lovastatin 20mg daily versus placebo	elderly (mean 71y) with low-density lipoprotein cholesterol levels greater than 4.1 and less than 5.7 mmol/L	Parallel groups double blind
<b>pravastatin vs placebo</b>			
<b>CARE (elderly subgroup) , 1998</b> n=640/643 follow-up: 5.0y	-	MI 320 months, subgroup of age 65-75 y	parallel groups double blind
<b>LIPID (elderly sub group) , 2001</b> n=1741/1773 follow-up: 6.1y	-	MI or unstable angina, subgroup of age 65-75 y	parallel groups double blind
<b>PLAC I (elderly sub group) , 1995</b> n=42/52 follow-up: 2.3y	-	Angiographic CAD or recent MI, subgroup of age 65-75 y	parallel groups double blind
<b>REGRESS (elderly subgroup) , 1995</b> n=75/63 follow-up: 2.0y	-	Angiographic CAD, subgroup of age 65-70 y	parallel groups double blind
<b>PROSPER , 2002</b> n=2891/2913 follow-up: 3.2 years	pravastatin 40mg daily versus placebo	men and women aged 70-82 years with a history of, or risk factors for, vascular disease	Parallel groups double blind Ecosse, Irlande, Pays bas
<b>rosuvastatin vs placebo</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>JUPITER (elderly sub group) , 2009</b> n=5695 follow-up: double-blind	rosuvastatin 20mg daily versus placebo	healthy individuals aged $\geq 70$ years with normal LDL cholesterols but with CRP levels $\geq 2.0$ mg/dL	Parallel groups double blind
<b>simvastatin vs placebo</b>			
<b>4S (elderly subgroup) , 1997</b> n=518/503 follow-up: 5.4y	-	MI 6 months or stable angina, subgroup of age 65-70 y	parallel groups double blind
<b>HPS (elderly subgroup) , 2002</b>  n=5366/5331 follow-up: 5.0y	-	Vascular disease or diabetes, subgroup of age 65-80 y	parallel groups double blind

## References

### **FLARE (elderly subgroup), 1999:**

Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. *Eur Heart J* 1999;20:58-69 [10075142]

Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. *Eur Heart J* 1999;20:58-69 [10075142]

### **LIPS (elderly subgroup), 2002:**

Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;287:3215-22 [12076217]

### **CRISP 20mg, 1994:**

LaRosa JC, Applegate W, Crouse JR 3rd, Hunninghake DB, Grimm R, Knopp R, Eckfeldt JH, Davis CE, Gordon DJ Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. *Arch Intern Med* 1994;154:529-39 [8122946]

Stoy DB, Curtis RC, Dameworth KS, Dowdy AA, Hegland J, Levin JA, Sousoulas BG The successful recruitment of elderly black subjects in a clinical trial: the CRISP experience. *Cholesterol Reduction in Seniors Program. J Natl Med Assoc* 1995;87:280-7 [7752281]

### **CARE (elderly subgroup), 1998:**

Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. *Ann Intern Med* 1998;129:681-9 [9841599]

### **LIPID (elderly sub group), 2001:**

Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. *Ann Intern Med* 2001;134:931-40 [11352694]

### **PLAC I (elderly sub group), 1995:**

Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. *J Am Coll Cardiol* 1995;26:1133-9 [7594023]

### **REGRESS (elderly subgroup), 1995:**

Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1995;91:2528-40 [[7743614](#)]

**PROSPER, 2002:**

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360:1623-30 [[12457784](#)]

**JUPITER (elderly sub group), 2009:**

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. *Ann Intern Med* 2010;152:488-96, W174 [[20404379](#)] [10.1059/0003-4819-152-8-201004200-00005](#)

**4S (elderly subgroup), 1997:**

Miettinen TA, Pyrl K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) *Circulation* 1997;96:4211-8 [[9416884](#)]

**HPS (elderly subgroup), 2002:**

Champagne J, Geelen P, Philippon F, Brugada P Recurrent cardiac events in patients with idiopathic ventricular fibrillation, excluding patients with the Brugada syndrome. *BMC Med* 2005;3:1 [[15627402](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.